Category Archives: Pancreatic Cancer
Lack of Pancreatic Cancer Radiologic Improvement May NOT be an Accurate Measure of Neoadjuvant Success – an important and intriguing finding.
Researchers from the University of Texas / MD Anderson Cancer Center published an interesting recent study in the journal Cancer on the treatment and assessment of so-called neoadjuvant therapy in borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas). “Neoadjuvant” is a word that denotes typically the medical and/or radiological treatment of pancreatic cancer BEFORE […]
Canzian and estimable European colleagues including Dr. John Neoptolemos of Liverpool University (and again our Professor Markus Buchler of the University of Heidelberg / Pancreatica Science Board) in a February 2013 article in the Cancer Epidemiology, Biomarkers, and Prevention – a publication of the American Association for Cancer Research through their newly formed collaborative called […]
Spanish research Fulgar and colleagues published a recent article in the journal Anticancer Research detailing the results of their multi-center Phase 2 clinical trial evaluating oral erlotinib (Tarceva – 150 mg per day) coupled with the also orally administered capecitabine (Xeloda) in pancreatic cancer (ductal adenocarcinoma of the pancreas). Capecitabine is a pro-drug of 5-FU […]